Receptor for Advanced Glycation End Products: Dementia and Cognitive Impairment

Abstract

The pathophysiological processes of dementia and cognitive impairment are linked to advanced glycation end products (AGEs) and their receptor (RAGE).The neurofibrillary tangles (NFTs) of abnormally hyperphosphorylated tau protein and senile plaques (SPs), which are brought on by amyloid beta (Aβ) deposition, are the hallmarks of Alzheimer’s disease (AD), a progressive neurodegenerative condition. Advanced glycation end products that are produced as a result of vascular dysfunction are bound by the receptor for advanced glycation end products (RAGE). Dementia and cognitive impairment could develop when RAGE binds to Aβ and produces reactive oxygen species, aggravating Aβ buildup and ultimately resulting in SPs and NFTs. RAGE could be a more powerful biomarker than Aβ because it is implicated in early AD. The resident immune cells in the brain known as microglia are essential for healthy brain function. Microglia is prominent in the amyloid plaques’ outside border as well as their central region in Alzheimer’s disease. Microglial cells, in the opinion of some authors, actively contribute to the formation of amyloid plaques. In this review, we first discuss the early diagnosis of dementia and cognitive impairment, and then detail the interaction between RAGE and Aβ and Tau that is necessary to cause dementia and cognitive impairment pathology, and it is anticipated that the creation of RAGE probes will help in the diagnosis and treatment of dementia and cognitive impairment.

Key words

AGE - dementia - cognitive impairment - aβ - tau - senile plaques

• References

• 1 Biessels GJ. Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review.  Lancet Neurol 2006; 5: 64-74
• 2 Lovestone S. Smith U. Advanced glycation end products, dementia, and diabetes. Proc Natl Acad Sci USA 2014; 111: 4743-4744
• 3 Singh R. , Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146
• 4 Münch G. Westcott B, Menini T, Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders.  Amino Acids 2012; 42: 1221-1236
• 5 LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2’,7’-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 1992; 5: 227-231
• 6 Olivieri G, Brack C, Muller-Spahn F. et al. Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J Neurochem 2000; 74: 231-236
• 7 Sun Q, Hu H, Wang W. et al. Taurine attenuates amyloid beta 1-42-induced mitochondrial dysfunction by activating of SIRT1 in SK-N-SH cells. Biochem Biophys Res Commun 2014; 447: 485-489
• 8 Yuyun X, Jinjun Q, Minfang X. et al. Effects of Low Concentrations of Rotenone upon Mitohormesis in SH-SY5Y Cells. Dose Response 2013; 11: 270-280
• 9 Yang Y. et al. Target discovery from data mining approaches. Drug Discov Today 2009; 14: 147-154
• 10 Xie L. et al. Drug discovery using chemical systems biology: identification of the protein – ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol 2009; 5: E1000387
• 11 Goh KI. et al. The human disease network. Proc Natl Acad Sci USA 2007; 104: 8685-8690
• 12 Loscalzo J. et al. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 2007; 3: 124
• 13 Hu G, Agarwal P. Human disease-drug network based on genomic expression profiles. PLoS One 2009; 4: E6536
• 14 Stegmaier P. et al. Molecular mechanistic associations of human diseases. BMC Syst. Biol 2010; 4: 124
• 15 Vidal M. et al. Interactome networks and human disease. Cell 2011; 144: 986-998
• 16 Hidalgo CA. et al. A dynamic network approach for the study of human phenotypes. PLoS Comput. Biol 2009; 5: E1000353
• 17 Li GW, Xie XS. Central dogma at the single-molecule level in living cells. Nature 2011; 475: 308-315
• 18 Fenimore PW, Frauenfelder H, McMahon BH. et al. Slaving: solvent fluctuations dominate protein dynamics and functions. Proceedings of the National Academy of Sciences 2002; 99: 16047-16051
• 19 Fitzpatrick AW, Debelouchina GT, Bayro MJ. et al. Atomic structure and hierarchical assembly of a cross-β amyloid fibril. Proceedings of the National Academy of Sciences 2013; 110: 5468-5473
• 20 Jimenez JL, Guijarro JI, Orlova E. et al. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. The EMBO journal 1999; 18: 815-821
• 21 Hussain R, Zubair H, Pursell S. et al. Neurodegenerative diseases: Regenerative mechanisms and novel therapeutic approaches. Brain sciences 2018; 8: 177
• 22 Hussain R, Zubair H, Pursell S. et al. Neurodegenerative diseases: Regenerative mechanisms and novel therapeutic approaches. Brain sciences 2018; 8: 177
• 23 Cicero CE, Mostile G, Vasta R. et al. Santo Signorelli, S., Ferrante, M.,& Nicoletti, A. Metals and neurodegenerative diseases. A systematic review. Environmental research 2017; 159: 82-94
• 24 Gardner RC, Yaffe K. Epidemiology of mild traumatic brain injury and neurodegenerative disease. Molecular and Cellular Neuroscience 2015; 66: 75-80
• 25 Rezazadeh M, Khorrami A, Yeghaneh T. et al. Genetic factors affecting late-onset Alzheimer’s disease susceptibility. Neuromolecular medicine 2016; 18: 37-49
• 26 Zhao Y, Luo P, Guo Q. et al. Interactions between SIRT1 and MAPK/ERK regulate neuronal apoptosis induced by traumatic brain injury in vitro and in vivo. Exp Neurol 2012; 237: 489-498
• 27 Khan RS, Dine K, Das Sarma J. et al. SIRT1 activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease. Acta Neuropathol Commun 2014; 2: 3
• 28 Khan RS, Fonseca-Kelly Z, Callinan C. et al. SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells. Front Cell Neurosci 2012; 6: 63
• 29 Li J, Feng L, Xing Y. et al. Radioprotective and antioxidant effect of resveratrol in hippocampus by activating Sirt1. Int J Mol Sci 2014; 15: 5928-5939
• 30 Ye Q, Ye L, Xu X. et al. Epigallocatechin-3-gallate suppresses 1- methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1alpha signaling pathway. BMC Complement Altern Med 2012; 12: 82
• 31 Aso E, Semakova J, Joda L. et al. Triheptanoin supplementation to ketogenic diet curbs cognitive impairment in APP/PS1 mice used as a model of familial Alzheimer’s disease. Curr Alzheimer Res 2013; 10: 290-297
• 32 Singh A, Ansari VA, Mahmood T. et al. Neurodegeneration: Microglia: Nf-Kappab Signaling Pathways. Drug Research. 2022
• 33 Singh A, Ansari VA, Mahmood T. et al. Dendrimers: A Neuroprotective Lead in Alzheimer Disease: A Review on its Synthetic approach and Applications. Drug Research. 2022